Status:

COMPLETED

Exercise Training in Patients With Left Ventricular Assist Device

Lead Sponsor:

Charite University, Berlin, Germany

Collaborating Sponsors:

Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

University of Göttingen

Conditions:

Heart Failure

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The objective of the study is to test whether 12 weeks of structured supervised exercise training on top of usual care improves functional capacity in patients with end-stage heart failure with contin...

Eligibility Criteria

Inclusion

  • chronic end-stage systolic heart failure
  • stable on left ventricular assist device, meaning
  • no major change in therapeutic regime within past 4 weeks: no new additional disease modifying drug (ACE inhibitor, ARB, sacubitril, beta-blocker), no change in disease modifying drug dosage more than 50% (excluded: diuretics), no initiation of a cardiac rehabilitation for a minimum of 4 weeks
  • post implantation ≥ 3 months
  • expected further period on the device for a minimum of 3 months after recruitment into the study
  • ability to complete the study in compliance with the protocol.
  • general ability of the patient to declare willingness to participate in the trial.
  • written informed consent

Exclusion

  • acute illness that does not allow exercise, including unstable heart failure, acute myocarditis, acute pericarditis, stroke
  • untreated life-threatening cardiac arrhythmias
  • uncontrolled hypertension
  • intracardiac thrombus
  • inability to perform cardiopulmonary exercise testing at least 1 minute at 20W
  • uncontrolled diabetes
  • uncontrolled kidney disease
  • recent embolism
  • concurrent, continuous, or intermittent dobutamine therapy
  • complex ventricular arrhythmia at rest or appearing with exertion
  • supine resting heart rate \> 100 beats per minute
  • severe pulmonary instability
  • hemodynamically relevant valvular disorders
  • significant change in cardiovascular medication within the previous 4 weeks (see inclusion criteria)
  • severe anemia (hemoglobin \<8 g/dl), however patients with moderate anemia (hemoglobin \<11 g/dl) may be recruited if clinically stable (investigator assessment)
  • clinically relevant musculoskeletal disease

Key Trial Info

Start Date :

December 4 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2020

Estimated Enrollment :

64 Patients enrolled

Trial Details

Trial ID

NCT03369938

Start Date

December 4 2017

End Date

December 31 2020

Last Update

January 27 2021

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Charité - Universitätsmedizin Berlin und Deutsches Herzzentrum Berlin

Berlin, Germany, 13353

2

Universitätsklinikum Düsseldorf

Düsseldorf, Germany, 40225

3

Universitätsklinikum Hamburg-Eppendorf

Hamburg, Germany, 20246

4

Herzzentrum Leipzig

Leipzig, Germany, 04289